Abstract
Congenital abnormalities and impaired development in childhood are attributable to fetal exposure to antiepileptic drugs (AEDs). Pregnancy registries set up to obtain information about the potential risks of fetal exposure to AEDs, in particular major congenital malformations (MCMs), suggest that valproate exposure increases the frequency of congenital malformations more than other AEDs. Furthermore, follow-up studies have drawn attention to cognitive impairments in later childhood after prenatal exposure to valproate. Fetal exposure to AEDs may be influenced by drug transporting proteins in the placenta, including P-glycoprotein (P-gp), multidrug resistance protein (MRP) 1, and breast cancer resistance protein (BCRP). Their location in the syncytiotrophoblast plasma membrane, at the interface of the maternal and fetal circulations, allows these transport proteins to efflux xenobiotics back to the mother and offers the fetus protection from medications taken during pregnancy. Genetic variations in the expression and activity of these transport proteins may influence fetal exposure to AEDs and thus the risk of teratogenicity. Identification of a hierarchy of haplotypes ranging from susceptible to protective of congenital abnormalities could assist genetic counseling, in assessing fetal risks from exposure to AEDs.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- AEDs:
-
antiepileptic drugs
- BCRP:
-
breast cancer resistance protein
- FACS:
-
fetal anticonvulsant syndrome
- MCMs:
-
major congenital malformations
- MDR1:
-
multidrug resistance protein
- MRP:
-
multidrug resistance–associated protein
- P-gp:
-
P-glycoprotein
- SNP:
-
single nucleotide polymorphism
References
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J 2006 Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193–198
Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J 2004 Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 3: CD004848
Ornoy A 2006 Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 22: 214–226
Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC 2006 In utero antiepileptic drug exposure: fetal death and malformations. Neurology 67: 407–412
Viinikainen K, Heinonen S, Eriksson K, Kalviainen R 2006 Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 47: 186–192
Atkinson DE, Boyd RD, Sibley CP 2006 Placental transfer. In: Neill JD (ed) Knobil and Neill's Physiology of Reproduction. Elsevier, pp. 2787–2846
Atkinson DE, Sibley CP, Fairbairn LJ, Greenwood SL 2006 MDR1 P-gp expression and activity in intact human placental tissue; upregulation by retroviral transduction. Placenta 27: 707–714
St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ 2000 Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279: R1495–R1503
Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH 2000 Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 294: 413–420
Doyle LA, Ross DD 2003 Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340–7358
Dean JC, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J 2002 Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 39: 251–259
Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW 2004 The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75: 1575–1583
EURAP Study Group 2006 Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 66: 354–360
Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A 2004 Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 190: 371–379
Pennell PB 2002 Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol 22: 299–308
Wide K, Winbladh B, Kallen B 2004 Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 93: 174–176
Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J 2005 Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64: 1874–1878
Holmes LB, Wyszynski DF, Lieberman E 2004 The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 61: 673–678
Vajda FJ, Eadie MJ 2005 Maternal valproate dosage and foetal malformations. Acta Neurol Scand 112: 137–143
Cunnington M, Tennis P 2005 Lamotrigine and the risk of malformations in pregnancy. Neurology 64: 955–960
Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D 1999 Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46: 739–746
Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T 1999 Congenital malformations due to antiepileptic drugs. Epilepsy Res 33: 145–158
Mawer G, Clayton-Smith J, Coyle H, Kini U 2002 Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 11: 512–518
Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah M, Chandranath SI 2003 Experimental studies on reproductive toxicologic effects of lamotrigine in mice. Birth Defects Res B Dev Reprod Toxicol 68: 428–438
Gaily E, Granstrom ML 1992 Minor anomalies in children of mothers with epilepsy. Neurology 42: 128–131
Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J 2006 Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 91: F90–F95
Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM 2001 The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132–1138
Adab N, Jacoby A, Smith D, Chadwick D 2001 Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 70: 15–21
Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E, Granstrom ML 2004 Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62: 28–32
Eriksson K, Viinikainen K, Monkkonen A, Aikia M, Nieminen P, Heinonen S, Kalviainen R 2005 Children exposed to valproate in utero—population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65: 189–200
Loscher W, Potschka H 2002 Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301: 7–14
Kwan P, Brodie MJ 2005 Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46: 224–235
Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C 1995 MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1–6
Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M 2002 Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125: 22–31
Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, Dini G, Vezzani A, Janigro D 2004 Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2: 37–47
Potschka H, Fedrowitz M, Loscher W 2002 P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327: 173–176
Potschka H, Fedrowitz M, Loscher W 2003 Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306: 124–131
Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W 2006 Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27: 602–609
Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ 2003 Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol 285: C584–C591
Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S, Nagata Y 1997 Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 235: 849–853
Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, Uchiumi T, Nakamura T, Kuwano M, Ohtani H, Sawada Y 2000 Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur J Pharmacol 408: 1–10
Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y 2003 Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm Res 20: 38–44
Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K 2005 Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 78: 123–131
Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH 1999 Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104: 1441–1447
Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR 1998 Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12: 457–463
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG 1992 Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654
Cole SP, Deeley RG 1998 Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20: 931–940
Pascolo L, Fernetti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C 2003 Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 303: 259–265
Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK 2005 Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 33: 896–904
Conseil G, Deeley RG, Cole SP 2005 Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 15: 523–533
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD 1998 A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665–15670
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH 2001 Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458–3464
Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH 2002 The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99: 15649–15654
van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, Schinkel AH 2003 The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 63: 6447–6452
Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F 2006 Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33: 58–65
Evseenko DA, Paxton JW, Keelan JA 2006 ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 290: R1357–R1365
Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH 2000 Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1651–1656
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473–3478
Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A 2005 Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6: 115–138
Schwab M, Eichelbaum M, Fromm MF 2003 Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43: 285–307
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG 2003 Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13: 481–494
Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG 2002 Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12: 437–450
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W 2005 Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693–704
Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U 2001 The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1: 204–210
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM 2003 Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348: 1442–1448
Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K 2006 ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7: 551–561
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K 2001 Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137–1143
Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M 2004 Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14: 309–318
Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K 2001 Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175–184
Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D 2001 Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46: 656–663
Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP 2002 A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12: 321–330
Leslie EM, Letourneau IJ, Deeley RG, Cole SP 2003 Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42: 5214–5224
Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y 2002 C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1: 611–616
Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE 2005 Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56: 161–172
Mizuarai S, Aozasa N, Kotani H 2004 Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109: 238–246
Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y 2005 Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94–101
Matalon S, Schechtman S, Goldzweig G, Ornoy A 2002 The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 16: 9–17
Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB 2005 Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64: 961–965
Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, Mamoli D, Palmieri C, Molteni F, Granata T, Hassibi P, Zamperini P, Pardi G, Avanzini G 1999 Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 40: 1231–1236
Kaaja E, Kaaja R, Hiilesmaa V 2003 Major malformations in offspring of women with epilepsy. Neurology 60: 575–579
Sabers A, Dam M, Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, Alving J, Dahl M, Ankerhus J, Mouritzen Dam A 2004 Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 109: 9–13
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Vajda F 2004 EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 45: 1463–1464
Diav-Citrin O, Shechtman S, Arnon J, Ornoy A 2001 Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 57: 321–324
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Atkinson, D., Brice-Bennett, S. & D'Souza, S. Antiepileptic Medication During Pregnancy: Does Fetal Genotype Affect Outcome?. Pediatr Res 62, 120–127 (2007). https://doi.org/10.1203/PDR.0b013e3180a02e50
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/PDR.0b013e3180a02e50
